MRI-Guided radiation may shrink inoperable colon tumors
NCT ID NCT06244537
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether a precise MRI-guided radiation technique (MR-Linac) can help shrink advanced colon cancers that cannot be surgically removed. Twenty participants will receive short-course radiation followed by chemotherapy, then surgery if possible. The goal is to see if this approach is safe and can make surgery an option.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- MR-Linac radiotherapy and chemotherapy (mFOLFOX6 or XELOX)
- What this could lead to
- If successful, this approach could make surgery possible for some patients with colon cancer that was previously considered inoperable.
- What could go wrong
- This is a very early, small phase I trial with only 20 participants. The combination of radiation and chemotherapy may cause significant side effects, and it is unknown if it will improve long-term outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 20 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: 1. Patients over 18 years old 2. Patients can remain in a stationary position on the treatment bed for 1-1.5 hours 3. ECOG score 0-1 4. Pathological diagnosis of colon adenocarcinoma, clinical stage cT4N0-2M0 5. Organ function is normal, and the following conditions are required: white blood cell count ≥3.5×10\^9/L; platelet count ≥100×10\^9/L; hemoglobin ≥90g/L. Total bilirubin level ≤1.5× upper limit of normal (ULN); AST and ALT levels ≤2.5 × ULN; endogenous creatinine clearance rate: 56-122ml/min; serum creatinine \<1.0× ULN; serum albumin ≥30g/L. 6. Able to adhere to the study protocol during the research period 7. Signed written informed consent Exclusion Criteria: 1. Patients with dMMR or MSI-H 2. Presence of other types of tumors in addition to colon adenocarcinoma 3. Claustrophobia or inability to undergo MRI or treatment due to the presence of metal implants or other reasons 4. Distant metastasis (M1) 5. Pregnant or lactating women 6. Previous anti-tumor treatment 7. Concurrent use of prohibited drugs for treatment 8. Known history of positive human immunodeficiency virus testing or known acquired immunodeficiency syndrome. 9. Clinically significant (i.e., active) cardiovascular disease: cerebrovascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina pectoris, congestive heart failure (≥New York Heart Association class II) or severe arrhythmia requiring medication treatment 10. Individuals with uncontrolled epilepsy, central nervous system disorders or a history of mental illness, whose clinical severity may hinder signing informed consent or affect patient compliance with oral medication according to the investigator's judgement 11. Organ transplant surgery requiring immunosuppressive therapy 12. Severe, uncontrolled recurrent infections or other severe, uncontrolled comorbidities
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Safety and efficacy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Sichuan Cancer Hospital & Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China.
RECRUITINGChengdu, Sichuan, 610042, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.